Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/1967/2/07: PCT prescribing lead v Novartis β€” alleged claim that Exforge was PCT-endorsed (No breach)

A PCT complained a Novartis rep said Exforge was endorsed by the PCT. Evidence suggested a misunderstanding between…

8 Mar 2026

AUTH/2967/8/17 – Consultant v Shire: Omission of prescribing information and other obligatory information (No breach / Out of scope)

PMCPA case AUTH/2967/8/17 (Consultant v Shire). Allegation: omission of prescribing and obligatory information. Outcome: no breach; matter found…

8 Mar 2026

Sanofi-Aventis & Bristol-Myers Squibb: MINAP meeting invitation misleadingly implied endorsement (AUTH/2029/7/07, AUTH/2030/7/07)

MINAP complained a sponsored meeting invite implied MINAP Steering Committee involvement/endorsement. Panel found the invitation misleading and not…

8 Mar 2026

AUTH/2354/9/10: Anonymous v Consilient Health β€” Promotion of oral contraceptives (out of scope; no breach)

PMCPA case AUTH/2354/9/10 (Anonymous v Consilient Health) about promotion of oral contraceptives. The matter was ruled outwith the…

8 Mar 2026

Napp: Invokana renal outcomes discussion at conference stand; internal CREDENCE training slides ruled to breach

Anonymous pharmacist alleged off-licence CKD promotion of Invokana at a diabetes conference. Panel couldn’t prove what was said…

8 Mar 2026

Roche and Chugai: complaint about allegedly out-of-date RoActemra prescribing information (no breach)

A UK health professional alleged RoActemra prescribing information in a Guidelines in Practice product review was out of…

8 Mar 2026

AUTH/3520/6/21: NHS commissioning manager v Sanofi (flu vaccine promotion/availability) – No breach

Complaint about Sanofi’s flu vaccine ordering communications and a 30% QIVe dose reduction (with QIVr as an alternative).…

8 Mar 2026

Stallergenes Greer: LinkedIn post naming POM brands ruled promotion to the public (AUTH/3570/10/21)

A corporate LinkedIn post named brands and an indication for a newly authorised SLIT tablet. PMCPA ruled this…

8 Mar 2026

Novartis breached Code over Kesimpta SMC β€œapproval” stamp and UK digital ad (missing β€˜adult’ + NI prescribing info) (AUTH/3643/5/22)

Kesimpta promo webpage implied unrestricted SMC approval (restriction not in immediate view). A UK HCP banner ad omitted…

8 Mar 2026

AUTH/3759/4/23: Boehringer Ingelheim clinical trial recruitment flyer at BSG Conference 2023 – No breach

Anonymous complaint alleged a Phase 2/3 sarcoma trial flyer in conference bags was pre-licence promotion and inappropriately distributed.…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training